CD70.CAR NK cell therapy (Bellicum Pharma)

N/A

Report date: 2026/04/25 20:00:23

Base Information

Drug NameCD70.CAR NK cell therapy (Bellicum Pharma)
Drug Alias NameCD70 CAR-NK cells therapy (Bellicum Pharma)
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord blood-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionAnti-CD70
TargetsCD70 antigen
Therapy Area/IndicationsLymphoma, B-CellHodgkin Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBellicum Pharmaceuticals IncThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesBellicum Pharmaceuticals IncThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellHodgkin Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A